Bloomberg has published an article about GSK’s overhaul of its R&D organization that describes former head of the allergic inflammation discovery performance unit Roberto Solari as “one of the casualties of the company’s new approach to drug discovery.” According to the article, a spokesperson for GSK confirmed that Solari, whom the author describes as “an unassuming 55-year-old scientist of Italian origin,” is no longer the team head, though he remains employed by the company.
Although the article discusses changes to the entire GSK R&D program, most of the researchers quoted are involved in respiratory research, including Dave Allen, Robin Carr, Malcolm Begg, Allison Ford, and Vicki Barrett, all of whom have positive things to say about the new system.
Read the Bloomberg article.
